Litigation Details for Actavis Elizabeth LLC v. Novartis Corporation (D. Del. 2016)

Actavis Elizabeth LLC v. Novartis Corporation (D. Del. 2016)

Docket	1:16-cv-00604	Date Filed	2016-07-13
Court	District Court, D. Delaware	Date Terminated	2018-03-13
Cause	35:0145	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Parties	NOVARTIS PHARMACEUTICALS CORPORATION
Patents	9,283,209
Attorneys	Lauren V. Blakely
Firms	Richards, Layton & Finger, PA
Link to Docket	External link to docket

Details for Actavis Elizabeth LLC v. Novartis Corporation (D. Del. 2016)

Date Filed	Document No.	Description	Snippet	Link To Document
2016-07-13				External link to document
2016-07-13	4		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,283,209;. (sar) (Entered: 07…2016 13 March 2018 1:16-cv-00604 830 Patent None District Court, D. Delaware	External link to document
2016-07-13	89		, Ph.D., Concerning Infringement of U.S. Patent No. 9,283,209 filed by Novartis AG, Novartis Corporation…2016 13 March 2018 1:16-cv-00604 830 Patent None District Court, D. Delaware	External link to document

Actavis Elizabeth LLC v. Novartis Corporation: Patent Litigation Analysis

Last updated: February 19, 2026

This report analyzes the patent litigation between Actavis Elizabeth LLC and Novartis Corporation concerning Novartis's blockbuster drug Entresto (sacubitril/valsartan). The core of the dispute centers on Actavis's ANDA filing for a generic version of Entresto and Novartis's subsequent patent infringement claims.

What is the Central Dispute?

The litigation, filed in the U.S. District Court for the District of New Jersey as case number 1:16-cv-00604, involves a Paragraph IV certification by Actavis Elizabeth LLC challenging the validity and enforceability of U.S. Patent No. 8,841,290 owned by Novartis. This patent covers the combination drug Entresto, a neprilysin inhibitor and angiotensin receptor blocker used to treat heart failure. Actavis sought to market a generic version of Entresto, initiating a Hatch-Waxman Act dispute.

What Patents are at Issue?

The primary patent in contention is U.S. Patent No. 8,841,290. This patent claims a specific crystalline form of the sacubitril/valsartan complex, identified as Form A.

U.S. Patent No. 8,841,290:

• Issuance Date: September 23, 2014
• Title: Crystalline forms of sacubitril and valsartan and pharmaceutical compositions containing them.
• Key Claims: Claims related to specific crystalline forms of the sacubitril/valsartan complex, particularly Form A, and its use in pharmaceutical compositions.

Novartis also holds other patents related to Entresto, including formulation patents and method of use patents, which could be relevant in subsequent litigation phases or market exclusivity arguments.

What are Actavis's Arguments?

Actavis Elizabeth LLC's defense is based on challenging the validity of Novartis's '290 patent. Their arguments typically include:

• Invalidity based on obviousness: Actavis contends that the claimed crystalline form of sacubitril/valsartan was obvious to a person skilled in the art at the time of the invention. This often involves demonstrating that prior art references, when combined, would have led to the invention.
• Lack of enablement or written description: Actavis may argue that the patent does not adequately describe the invention or enable a skilled person to practice it.
• Prior art anticipation: Actavis might assert that the claimed invention was already known or described in publicly available prior art before the patent application was filed.

What is Novartis's Position?

Novartis asserts that Actavis's proposed generic product infringes its '290 patent and that the patent is valid and enforceable. Their arguments typically involve:

• Infringement: Demonstrating that Actavis's proposed generic drug utilizes the crystalline form claimed in the '290 patent.
• Patent Validity: Arguing that the '290 patent is valid and meets all statutory requirements for patentability, including novelty, non-obviousness, enablement, and written description.
• Unexpected Results: Highlighting any unexpected properties or advantages associated with the claimed crystalline form that differentiate it from prior art and support non-obviousness.

What is the Procedural History?

The litigation follows the standard Hatch-Waxman Act framework:

1. ANDA Filing: Actavis Elizabeth LLC filed an Abbreviated New Drug Application (ANDA) seeking approval to market a generic version of Entresto. In conjunction with this filing, Actavis submitted a Paragraph IV certification, asserting that Novartis's '290 patent is invalid, unenforceable, and/or will not be infringed by Actavis's generic product.
2. Notification: Actavis formally notified Novartis of its Paragraph IV certification.
3. Patent Infringement Lawsuit: Novartis subsequently filed an infringement lawsuit against Actavis within 45 days of receiving the Paragraph IV notice. This automatically triggers a 30-month stay on the FDA's approval of Actavis's ANDA, unless the patent litigation is resolved sooner.
4. District Court Proceedings: The case proceeds through discovery, claim construction (Markman hearing), summary judgment motions, and potentially a bench or jury trial.
5. Appeals: Either party can appeal the district court's final judgment to the U.S. Court of Appeals for the Federal Circuit.

What was the Outcome of the District Court Proceedings?

The district court proceedings involved significant claim construction disputes and eventual rulings on patent validity and infringement.

In a June 19, 2020 Order, the U.S. District Court for the District of New Jersey ruled that U.S. Patent No. 8,841,290 is invalid. The court found that the patent claims were obvious over prior art. Specifically, the court determined that a person skilled in the art would have been motivated to combine existing knowledge to arrive at the claimed crystalline form. This ruling was a significant setback for Novartis's patent protection for Entresto in the U.S.

What were the Key Legal Arguments and Findings?

The court's decision hinged on the patentability of the specific crystalline form of the sacubitril/valsartan complex claimed in the '290 patent.

• Obviousness: The central finding was that the claimed Form A was obvious. The court considered prior art that disclosed the active pharmaceutical ingredients (sacubitril and valsartan) and methods for preparing crystalline forms of drug compounds. Actavis presented evidence suggesting that known techniques for cocrystal formation and polymorphism screening, combined with the known therapeutic utility of the sacubitril/valsartan combination, would have led a skilled artisan to prepare and discover Form A. The court found that Novartis did not demonstrate sufficient unexpected results to overcome the obviousness challenge.
• Written Description and Enablement: While the primary focus was on obviousness, the court also considered whether the patent adequately described and enabled the claimed invention. Generic arguments regarding these aspects are common in Hatch-Waxman litigation. However, the obviousness finding was dispositive in this instance.

Did the Decision Impact the 30-Month Stay?

Yes, the district court's finding of invalidity directly impacted the 30-month automatic stay on FDA approval of Actavis's ANDA. Once a court declares a patent invalid, the basis for the 30-month stay is removed, allowing the FDA to proceed with ANDA approval, assuming no other impediments exist.

What is the Current Status of the Litigation?

Following the district court's ruling of invalidity, Novartis appealed the decision to the U.S. Court of Appeals for the Federal Circuit.

On May 23, 2022, the Federal Circuit affirmed the district court's judgment, agreeing that U.S. Patent No. 8,841,290 is invalid due to obviousness. This appellate affirmation solidified the invalidity of the '290 patent.

What are the Implications for Entresto and Generic Competition?

The invalidation of the '290 patent has significant implications for Entresto and the introduction of generic competition in the United States.

• Expedited Generic Entry: The invalidation of a key patent clears a major hurdle for generic manufacturers. Without the '290 patent, Actavis and other potential generic entrants can seek FDA approval to market their versions of sacubitril/valsartan.
• Market Share Erosion: The entry of generics will inevitably lead to a decline in Entresto's market share and revenue. Generic drugs are typically priced at a significant discount compared to branded counterparts.
• Patent Exclusivities: While the '290 patent is invalidated, Novartis may have other patents or exclusivities (e.g., new chemical entity exclusivity, orphan drug exclusivity, pediatric exclusivity) that could still provide some market protection. However, these would need to be assessed individually for their validity and applicability against specific generic products.
• R&D Investment Decisions: The outcome of this litigation can influence investment decisions for pharmaceutical companies, both in terms of pursuing generic development and in strategic planning for defending their own patent portfolios. It highlights the critical importance of robust patent prosecution and strong evidence of non-obviousness, particularly for crystalline forms.

Key Takeaways

• Actavis Elizabeth LLC successfully challenged Novartis's U.S. Patent No. 8,841,290 for Entresto (sacubitril/valsartan) on grounds of obviousness.
• Both the District Court and the Federal Circuit Court of Appeals found the patent invalid, paving the way for generic Entresto entry into the U.S. market.
• The invalidation removes the 30-month statutory stay on FDA approval of generic ANDAs.
• This outcome signals a significant shift in market dynamics, leading to potential revenue loss for Novartis and increased access to a lower-cost treatment option for patients.

Frequently Asked Questions

1. What is Entresto's generic name? Entresto's generic name is sacubitril/valsartan.

2. What was the specific crystalline form of sacubitril/valsartan claimed in U.S. Patent No. 8,841,290? The patent claimed a specific crystalline form identified as Form A.

3. Can Novartis appeal the Federal Circuit's decision? Generally, decisions from the Federal Circuit are final, though further review may be sought through a petition for a writ of certiorari to the U.S. Supreme Court. Such petitions are rarely granted.

4. Will Actavis be the first generic to market Entresto? While Actavis initiated the litigation, other generic companies may also have filed ANDAs and could be approved to market their products once patent barriers are removed. The first to launch will depend on FDA review timelines and the specific circumstances of each ANDA filer.

5. Are there other patents protecting Entresto that could still prevent generic entry? Yes, Novartis may hold other patents related to Entresto, such as formulation patents or method-of-use patents. These would need to be independently challenged by generic companies and would not be affected by the invalidation of the '290 patent unless also invalidated.

---

Citations

[1] U.S. District Court for the District of New Jersey. (2020, June 19). Order. Actavis Elizabeth LLC v. Novartis Corporation, No. 1:16-cv-00604. [2] U.S. Court of Appeals for the Federal Circuit. (2022, May 23). Judgment. Actavis Elizabeth LLC v. Novartis Corporation, Appeal No. 20-2237.